EXOZYMES INC. Net Income
EXOZYMES INC. (EXOZ) reported Net Income of -$2.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-13
- EXOZYMES INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$2.88M.
- EXOZYMES INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$2.37M.
- EXOZYMES INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$2.66M.
- EXOZYMES INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$2.29M.
- EXOZYMES INC. net income (loss) attributable to parent for fiscal 2025 was -$9.16M.
- EXOZYMES INC. net income (loss) attributable to parent for fiscal 2024 was -$5.86M.
- EXOZYMES INC. net income (loss) attributable to parent for fiscal 2023 was -$2.04M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.88M 10-Q · filed 2026-08-13 | -$5.25M 10-Q · filed 2026-08-13 | -$7.90M derived: sum of 3 quarters · filed 2026-08-13 | -$10.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.37M 10-Q · filed 2026-08-13 | -$5.03M derived: sum of 2 quarters · filed 2026-08-13 | -$7.31M derived: sum of 3 quarters · filed 2026-08-13 | -$9.67M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$4.94M derived: sum of 2 quarters · filed 2026-03-30 | -$7.30M derived: sum of 3 quarters · filed 2026-08-13 | -$9.16M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$2.29M 10-Q · filed 2025-11-13 | -$4.65M derived: sum of 2 quarters · filed 2026-08-13 | -$6.50M 10-Q · filed 2025-11-13 | -$8.34M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$2.36M 10-Q · filed 2026-08-13 | -$4.22M 10-Q · filed 2026-08-13 | -$6.05M derived: sum of 3 quarters · filed 2026-08-13 | -$7.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.86M 10-Q · filed 2026-08-13 | -$3.69M derived: sum of 2 quarters · filed 2026-08-13 | -$5.35M derived: sum of 3 quarters · filed 2026-08-13 | -$6.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2024-12-31 | -$1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.49M derived: sum of 2 quarters · filed 2026-03-30 | -$4.85M derived: sum of 3 quarters · filed 2026-03-30 | -$5.86M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$1.66M 10-Q · filed 2025-11-13 | -$3.02M derived: sum of 2 quarters · filed 2025-11-13 | -$4.03M 10-Q · filed 2025-11-13 | -$5.12M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.36M 10-Q · filed 2025-11-13 | -$2.37M 10-Q · filed 2025-08-12 | -$3.47M derived: sum of 3 quarters · filed 2025-11-13 | -$3.99M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | -$1.01M 10-Q · filed 2025-11-13 | -$2.11M derived: sum of 2 quarters · filed 2025-11-13 | -$2.63M derived: sum of 3 quarters · filed 2025-11-13 | -$2.81M derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.62M derived: sum of 2 quarters · filed 2025-03-31 | -$1.80M derived: sum of 3 quarters · filed 2025-03-31 | -$2.04M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$520.60K 10-Q · filed 2024-11-12 | -$698.67K derived: sum of 2 quarters · filed 2024-11-12 | -$939.83K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$178.08K 10-Q · filed 2024-11-12 | -$419.23K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | -$241.15K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |